BRAF and thyroid gland carcinoma: In addition, a Japanese cross-organ phase II trial, the BELIEVE trial, including ten DTC and five ATC thyroid cancer patients with BRAF V600E/R or non-V600 BRAF mutations, reported a disease control rate (DCR) of 84% and a median PFS of 6.5 months, reinforcing the broader applicability of dabrafenib–trametinib in BRAF-driven thyroid tumors (61).